BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19247406)

  • 1. [Incorrect about hormone treatment in prostatic cancer].
    Fosså SD; Egey A; Haukaas SA; Angelsen A; Klepp O; Berge V; Axcrona K; Lilleby W
    Tidsskr Nor Laegeforen; 2009 Feb; 129(5):429. PubMed ID: 19247406
    [No Abstract]   [Full Text] [Related]  

  • 2. [Bicalutamide].
    Taéron C
    Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
    [No Abstract]   [Full Text] [Related]  

  • 3. [The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer].
    Sivko AV; Prokhorov AV
    Urol Nefrol (Mosk); 1997; (3):49-52. PubMed ID: 9245060
    [No Abstract]   [Full Text] [Related]  

  • 4. [Unreliable survival analysis].
    Tretli S; Kvåle R; Hernes E
    Tidsskr Nor Laegeforen; 2009 Feb; 129(5):429-30; author reply 430. PubMed ID: 19247405
    [No Abstract]   [Full Text] [Related]  

  • 5. No long-term effects of hormonal therapy preceding brachytherapy on urinary function and health-related quality of life among prostate cancer patients.
    Evers J; Kupper N; Kessing D; Davits R; Engelen A; Poortmans P; Mols F
    Urology; 2010 Nov; 76(5):1150-6. PubMed ID: 20869105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M; Lacombe L; Fradet Y
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].
    Rigatti P; Scattoni V
    Recenti Prog Med; 2002 Mar; 93(3):183-5. PubMed ID: 11942171
    [No Abstract]   [Full Text] [Related]  

  • 8. Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.
    Sternberg CN
    BJU Int; 2006 Mar; 97(3):435-8. PubMed ID: 16469001
    [No Abstract]   [Full Text] [Related]  

  • 9. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
    Lau YK; Chadha MK; Litwin A; Trump DL
    J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drug for prostate cancer.
    Eur J Cancer Care (Engl); 2001 Jun; 10(2):79-80. PubMed ID: 11829051
    [No Abstract]   [Full Text] [Related]  

  • 11. [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer].
    Rusakov IG; Alekseev BIa
    Urologiia; 2002; (5):23-6. PubMed ID: 12402771
    [No Abstract]   [Full Text] [Related]  

  • 12. [Reevaluation of MAB therapy and progress of endocrine therapy].
    Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
    Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
    [No Abstract]   [Full Text] [Related]  

  • 13. [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
    Martorana G
    Recenti Prog Med; 2002 Mar; 93(3):179-82. PubMed ID: 11942170
    [No Abstract]   [Full Text] [Related]  

  • 14. [Bicalutamide].
    Kotake T
    Nihon Rinsho; 2000 Jul; 58 Suppl():216-22. PubMed ID: 11022717
    [No Abstract]   [Full Text] [Related]  

  • 15. The third analysis of the bicalutamide Early Prostate Cancer programme.
    Iversen P;
    BJU Int; 2006 Mar; 97(3):438-9. PubMed ID: 16469002
    [No Abstract]   [Full Text] [Related]  

  • 16. New molecules and treatment modulation in advanced prostatic cancer.
    Mahler C; Verhelst J; Denis L
    Acta Urol Belg; 1996 May; 64(2):95-8. PubMed ID: 8701825
    [No Abstract]   [Full Text] [Related]  

  • 17. 'Casodex': defining the role of antiandrogens.
    McCaffrey JA; Scher HI
    Cancer J Sci Am; 1997; 3(4):204-8. PubMed ID: 9263624
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial comment.
    Shepard DR
    Urology; 2010 May; 75(5):1137. PubMed ID: 20451735
    [No Abstract]   [Full Text] [Related]  

  • 19. The place and the results of monotherapy.
    Bonnet P
    Acta Urol Belg; 1998 May; 66(2):11-5. PubMed ID: 9633120
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
    Yoshida T
    Int J Urol; 2013 Jul; 20(7):714-5. PubMed ID: 23216631
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.